Stockreport

Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer

Veru Inc.  (VERU) 
Last veru inc. earnings: 2/12 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: verupharma.com/investors
PDF -- Submits Investigational New Drug Application to FDA -- -- Open Label Phase 1b/2 Clinical Trial Expected to Begin before end of 2018 -- MIAMI, Nov. 13, 2018 (GLOB [Read more]